Articles describing the use of the
Dermatology Life Quality Index


1.             Finlay AY, Khan GK.  Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use.  Clinical and Experimental Dermatology 1994; 19: 210-216.

2.             Kurwa H, Finlay AY.  Dermatology inpatient management greatly improves life quality. British Journal of Dermatology 1995; 133: 575-578.

3.             Finlay AY.  Measures of the effect of severe atopic eczema on quality of life.  Journal of the European Academy of Dermatology and Venereology, 1996; 7: 149-154.

4.             Blackford S, Roberts DL, Salek MS, Finlay AY.  Basal cell carcinomas cause little handicap.  Quality of Life Research 1996; 5: 191-194.

5.             Nichol MB, Margoilies JE, Lippa E, Rowe M, Quell J.  The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis.   Pharmacoeconomics 1996; 10: 644-653.

6.             Kent G,  Al-Abadie M.  Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers.  Clinical and Experimental Dermatology 1996; 21: 330-333.

7.             Harris A, Burge SM, Dykes PJ, Finlay AY.  Handicap in Darier’s disease and Hailey-Hailey disease.  British Journal of Dermatology 1996; 135: 959-963.

8.             Piletta P A, Wirth S et al.  Circulating skin-homing T cells in atopic dermatitisArch Dermatol 1996; 132: 1171-1176.

9.             Jemec GB, Wulf HC.  Patient-physician consensus on quality of life in dermatology.  Clinical and Experimental Dermatology 1996; 21: 177-179.

10.         Blackford S, Finlay AY, Roberts DL.  Quality of life in Behcets’ syndrome: 
335 patients surveyed.
  British Journal of Dermatology 1997; 136: 293.

11.         Herd RM, Tidman MJ, Ruta DA, Hunter JAA.  Measurement of quality of life in atopic dermatitis: correlation and validation of two different methods British Journal of  Dermatology 1997; 136: 502-507.

12.         Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay A.  The effectiveness of acne treatment: an assessment by patients of the outcome of therapy.  British Journal of Dermatology 1997; 137: 563-567.

13.         Finlay AY.  Quality of life measurement in dermatology: a practical guide.  British Journal of Dermatology 1997; 136: 305-314.

14.         Finlay AY.  Dermatology Life Quality Index: initial experience of a simple practical measure.    Chapter in: Care management of skin disease: Life quality and economic impact.  Editors: R Rajagopalan, E.F. Sherertz, R.T. Anderson.  Marcel Dekker, New York 1998 p85-94.

15.         de Tiedra AG, Mercadal J, Badia X, Mascar JM, Lozano R.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.  Pharmacoeconomics 1998; 14: 405-422.

16.         de Tiedra AG, Mercadal J, Badia X, Mascar JM, Herdmann M, Lozano R.  Adaptacin transcultural al Espaol del cuestionario Dermatology Life Quality Index (DLQI): el ndice de Calidad de Vida en Dermatologia.  Actas Dermo-Sifiliograficas 1998; 89: 692-700.

17.         Grosshans E et al.  Evaluation of clinical efficacy and safety of adapelene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life.  British Journal of Dermatology 1998; 139 (Suppl 52): 26-33.

18.         Iliev D, Furrer L, Elsner P.  Estimating the quality of life of dermatologic patients.  Hautarzt 1998; 49: 453-456.

19.         Finlay AY.  Quality of life assessments in dermatology.  Seminars in Cutaneous Medicine and Surgery 1998; 17: 291-296.

20.         Bagel J, Garland W T, Breneman D et al.  Administration of DAB 389 IL-2 to patients with recalcitrant psoriasis:  A double-blind, phase II multicentre trial. 
J Am Acad of Dermatol 1998; 38: 938-944.

21.         Papadopoulos L et al.  Coping with the disfiguring effects of vitiligo.  British Journal of Medical Psycholog 1999; 72: 385-396.

22.         Linnet J, Jemec GBE.  An assessment of anxiety and dermatology life quality in patients with atopic dermatitis.  British Journal of Dermatology 1999; 140: 268-272.

23.         Poon E, Seed PT, Greaves MW, Kobza-Black A.  The extent and nature of disability in different urticarial conditions.  British Journal of Dermatology 1999; 140: 667-671.

24.         Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY.  The quality of life in acne: a comparison with general medical conditions using generic questionnaires.   British Journal of Dermatology 1999; 140: 672-676.  

25.         Badia X, Mascaro JM, Lozano R.  Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensibility to change of the DLQI.  British Journal of Dermatology 1999; 141: 698-702.

26.         Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M.  Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema.  British Journal of Dermatology 1999; 141: 1067-1075.

27.         Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U.  Quality of life in skin diseases:  methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis.  Hautarzt 1999; 50: 715-22.

28.         Giess R, Naumann M, Werne E, Riemann R, Beck M, Puls I, Reiners C, Toyka K V.  Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. 
J Neurol Neurosurg Psychiatry 2000; 69: 121-123
.

29.         Shum RW, Lawton S, Williams HC, Docherty G, Jones J.  The British Association of Dermatologists audit of atopic eczema management in secondary care.  Phase 3:  audit of service outcome.  British Journal of Dermatology 2000; 142: 721-727.

30.         Czech W, Brautigam M, Weidinger G, Schopt F.  A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life.  J Am Acad Dermatol 2000; 42: 653-659.

31.         Zachariae R, Zachariae C. Ibsen H, Mortensen J T, Wulf H C.  Dermatology life quality index:  data from Danish inpatients and outpatients.  Acta Derm Venereol 2000; 80: 272-276.

32.         Kernick D, Cox A, Powell R, Reinhold D, Sawkins J, Warin A.  A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis.  British Journal of General Practice 2000; 50: 555-558.

33.         Ayyalaraju R S, Finlay A Y.  Inpatient Dermatology:  United Kingdom and United States similarities.  Chapter in Dermatologic Clinics Inpatient Dermatology.  Eds F A Kerdel, R S  Kisner. W B Saunders Co, Philadelphia Dermatologic Clinics 2000; 18(3): 397-404

34.         Finlay A Y  Dermatology patients:  what do they really need?  Clin Exp Dermatol 2000; 25: 444-450

35.         Marks R, Plunkett A, Merlin K, Jenner N.  Atlas of Common Skin Diseases in Australia.  University of Melbourne, Melbourne 2000 p9, 15, 19.

36.         Harlow D, Poyner T, Finlay A Y, Dykes P J.  Impaired quality of life in adults with skin disease in primary care.  British Journal of Dermatology 2000; 143: 979-982.

37.         Haynes M.  Examining day-case and in-patient psoriasis care.  Professional Nurse 2000; 16: 893-896.

38.         Vensel E, Hilley T, Trent J, et al Sustained improvement of the quality of life of patients with psoriasis after hospitalisation.  J Am Acad Dermatol 2000; 43: 858-860.

39.         Jobanputra R, Bachmann M.  The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa.  International Journal of Dermatology 2000; 39: 826-831.

40.         Halioua B, Beumont M G.  Quality of life in dermatology.  International Journal of Dermatology 2000; 39: 801-806

41.         Thompson A K, Finn A F, Schoenwetter W F.  Effect of 60 mg twice-daily Fexofenadine HCI on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria.  Journal of the American Academy of Dermatology 2000; 43: 24-30

42.         Klassen A F, Newton J N, Mallon E.  Measuring quality of life in people referred for specialist care of acne:  comparing generic and disease-specific measuresJournal of the American Academy of Dermatology 2000; 43: 229-233.

43.         Lundberg L, Johannesson M, Silverdahl M et alHealth-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity.  Acta Derm Venereol 2000; 80: 430-434.

44.         Drake L, Prendergast M, Maher R et al.  The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitisJ Am Acad Dermatol 2001; 44: S65-S72.

45.         Finlay A Y.  Psoriasis from the patient’s point of view.  Arch Dermatol 2001; 137:  352-353

46.         Von Der Werth J  M, Jemee G B E.  Morbidity in patients with hidradenitis urativa. 
Br J Dermatol 2001; 144: 809-813.

47.         Ho V C Y, Griffiths C E M, Berth-Jones J et alIntermittent short courses of cyclosporin microemulsion for the long-term management of psoriasis:  a 2 year cohort study.   J Am Acad Dermatol 2001; 44: 643-651.

48.         Jemec BG B E, Kynemund L.  Time spent on treatment in dermatology - how much time do outpatients use and is it a measure of morbidity?  Acta Dermatoven APA 2001; 10:17-19

49.         Touw C R, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten F F H, Finlay A Y Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.  Br J Dermatol 2001; 144: 967-972

50.         Swartling C, Naver H, Lindberg M.  Botulinum A toxin improves life quality in severe primary focal hyperhidrosis.  Eur J Neurol 2001; 8: 247-52

51.         Williamson D, Gonzalez M, Finlay A Y.  The effect of hair loss on quality of life. 
J Eur Acad of Dermatol & Venereol 2001; 15: 137-139.

52.         Hahn BH, Melfi CA, Chuang T Y et al.  Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US Urban Clinic.  J Am Acad Dermatol 2001; 45: 44-48.

53.         Williams T L, May C R, Esmail A, et al.  Patient satisfaction with teledermatology is related to perceived quality of life.  Br J Dermatol 2001; 145: 911-917.

54.         Poli F, Dreno B, Vershoores M.  An epidemiological study of acne in female adults:  results of a survey conducted in France.  JEADV 2001; 15: 541-545

55.         Hutchings C V, Shum K W, Gawkrodger D J.  Occupational contact dermatitis has an appreciable impact on quality of life.  Contact Dermatitis 2001; 45(1): 17-20.

56.         Schafer T, Staudt A, Ring J.  German instrument for the assessment of quality of life in skin diseases (DIELH).  Internal consistency, reliability, convergent and discriminant validity and responsiveness.  Hautarzt 2001; 52(7): 624-628.

57.         Swan M C, Paes T.  Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhydrosis.  Ann Chir Gynaecol 2001; 90(3): 157-159.

58.         Hiltscher D, Boslet W T, Fuchslocher M et al.  Quality of life in patients with rosacea and rhinophymaAkt Dermatol 2001; 27:  391-394

59.         Thomson K F, Wilkinson S M, Sommer S, Pollock B.  Eczema: quality of life by body site and the effect of patch testing.   Br J Dermatol 2002; 146: 627-630.

60.         Mork C & Wahl A, Polit R N.  Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands.  J Am Acad Dermatol 2002; 47: 314-36.

61.         Hermansen S E, Helland C A, Finlay A Y.  Patients’ and doctors’ assessment of skin disease handicap.  Clin & Exp Dermatol 2002; 27: 249-250.

62.         Kiebert G, Sorensen S V, Revicki D, Fagan, S C, Doyle J J, Cohen J, Fivenson D.  Atopic dermatitis is associated with a decrement in health-related quality of life.  Int J Dermatol 2002; 41: 151-8.

63.         Jayaprakasam A, Darvey A, Osborne G, McGibbon D.  Comparisons of assessment of severity and quality of life in cutaneous disease.  Clin Exp Dermatol 2002; 27: 306-8.

64.         Gradwell C, Thomas K S, English J S, Williams H C. A randomised controlled trial of nurse follow-up clinics: do they help patients and free up consultants’ time?  Br J Dermatol 2002; 147: 513-517.

65.         Hachem J P, DePaepe K, Sterckx G, Kaufman L, Rogiers V, Roseeuw D.  Evaluation of key biographical and clinical parameters of skin barrier function among hospital workers.  Contact Dermatitis 2002; 46: 220-223.

66.         Holme S A, Beattie P E, Fleming C J. Cosmetic camouflage advice improve quality of life.  Br J Dermatol 2002; 147: 946-949.

67.         Mork C, Wahl A, Moum T.  The Norwegian version of the Dermatology Life Quality Index:  a study of validity and reliability in psoriaticsActa Derm Venereol 2002; 82: 347-351.

68.         Loo W-J, Lanigan S W.  Laser treatment improves quality of life of hirsute females.  Clin & Exp Dermatol 2002; 27(6): 439-441.

69.         Fivenson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y.  The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002; 8(5): 333-342

70.         Horn H M, Tidman M J.  Quality of life in epidermolysis bullosa.  Clin Exp Dermatol 2002; 27(8):  707-710.

71.         Boehncke W H, Ochsendorf F, Paeslack I, Kaufmann R, Zollner T M.  Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases.  Eur J Dermatol  2002; 12(6): 577-580.

72.         Helbling I, Ferguson J E, McKenna M, Muston H L.  Audit of admissions to dermatology beds in Greater Manchester.  Clin & Exp Dermatol 2002; 27: 519-522.

73.         Meurer M, Folster-Holst R, Wozel G, Weindinger G, Junger M, Brautigam M.  Primecrolimus cream in the long-term management of atopic dermatitis in adults:  A six-month study.  Dermatology 2002; 205(3): 271-277.

74.         McPherson T.  Impact on the quality of life of lymphoedema patients following introduction of a hygiene and skin care regimen in a Guyanese community endemic for lymphatic filariasis: A preliminary clinical intervention study. Filaria Journal 2003; 2: 1

75.         Parsad D, Pandhi R, Dogra S, Kanwar A J, Kumar B.  Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003; 148; 2: 373-374.

76.         Loo W-J, Diba V, Chawla M, Finlay A Y.  Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003; 148:  279-284.

77.         Ellis C N, Mordin M M Adler E Y.  Effects of Alefacept on health-related quality of life in patients with psoriasis:  Results from a randomised, placebo controlled phase II trial.  Am J Clin Dermatol 2003; 4(2):  131-139.

78.         Campanati A, Penna L, Guzzo T, Menotta L, Silvestri B, Lagalla G, Gesuita R, Offidani.  Quality of life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin:  results of an open-label study.  Clin Ther 2003; 25: 298-308.

79.         Reilly M C, Lavin P T, Kahler K H, Pariser D M.  Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment - Chronic Hand Dermatitis questionnaire in chronic hand dermatitis.  J Am Acad Dermatol 2003; 48: 128-130.

80.         Pittler M H, Armstrong N C, Cox A, Collier P M, Hart A & Ernst E.  Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis.   Br J Dermatol 2003; 148(2): 307-313.

81.         Chan J J, Gebeuer K.  Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab).  Australas J Dermatol 2003; 44(2): 116-20.

82.         Finlay A Y, Salek M S, Haney J.  Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis.  Dermatology 2003; 206(4): 307-315.

83.         Charman C. Chambers C, Williams H.  Measuring atopic dermatitis severity in randomized controlled clinical trails:  What exactly are we measuring?  J Invest Dermatol 2003; 120 (6): 932-941.

84.         Finlay A Y.  The impact of acne on quality of lifeJ Am Acad Dermatol 2003; 49: 133-135.

85.         Woo P N, Hay I C, Ormerod A D.  An audit of the value of patch testing and its effect on quality of life.  Contact Dermatitis 2003; 48: 244-247.

86.         McKenna S P, Cook S A, Whalley D, Doward L C, Richards H L, Griffiths C E M, Van Assch D.  Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.  Br J Dermatol 2003; 149(2):
323-331.

87.         Mazzotti E, Picardi A, Sampogna F, Sera F, Pasqunini P, Abeni D,.  The Idi multipurpose psoriasis research on vital experiences (improve) study group.  Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003 149(2): 318-322.

88.         Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A.  Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States:  A comparative study.  JAAD 2003; 49: 249-254.

89.         Schmid-ott G, Burchard R, Niederauer H H, Lamprecht F,Kunsebeck H W. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis.  Hautarzt 2003; 54(9): 852-857.

90.         Balkrishnan R, McMichael A J, Camacho F T, Saltzberg F, Housman Grummer S, Feldman S R, Chren M M.  Development and validation of a health-related quality of life instrument for women with melasma.  Br J Dermatol 2003; 149(3): 572-577.

91.         Carlin C S, Feldman S R, Krueger J G, Menter A Krueger C G.  A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint.  J Invest Dermatol 2003; 121(1): 0393. and JAAD 2004; 50(6): 859-866.

92.         Skoet R, Zachariae R, Agner T.  Contact dermatitis and quality of life:  a structured review of the literature.  Br J Dermatol 2003; 149: 452-456.

93.         Weisman S, Pollack C R, Gottschalk R W.  Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.  J Dermatol Treatment 2003; 14: 158-165.

94.         Shikiar R, Bresnahan B W, Stone S P, Thompson C, Koo J, Revicki D A, Validity and reliability of patient reported outcomes used in psoriasis:  results of two randomised clinical trials.  Health Qual Life Outcomes  2003; 1(1): 53.

95.         Bergstrom K G, Arambula K, Kimball A B.  Medication formulation affects quality of life: randomized single-blind study clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.0.5% for the treatment of psoriasis.  Cutis 2003; 72(5): 407-411.

96.         Gordon K B, Papp K A, Hamilton T K, Walicke P A, Dummer W, Li N, Bresnanhan B W, Menter A.  Efalizumab for patients with moderate to severe plaque psoriasis: a random controlled trial.  JAMA 2003; 290(23): 3073-3080.

97.         Gottlieb A B, Matheson R T, Low N, Krueger G G, Kang S, Goffe B S, Gaspari A A, Ling M, Weinstein G D, Nayak A, Gordon K B, Zitnik R.  A randomized trial of etanercept as monotherapy for psoriasis.  Arch Dermatol 2003; 139: 1627-1632.

98.         Leonardi C L, Powers J L, Matheson R T, Goffe B S, Zitnik R, Wang A, Gottlieb A B, for the Etanercept Psoriasis Study Group.  Etanercept as monotherapy in patients with psoriasis.  New England J of Med 2003; 349 21: 2014-2022.

99.         Krueger G G, Callis K P.  Development and use of alefacept to treat psoriasis.   Am Acad Dermatol 2003; 49 (2): S87-S97.

100.     Leonardi C L.  Efalizumab:  An overview.  Am Acad Dermatol 2003; 49 (2): S98-S104.

101.     Goffe B, Cather J C.  Etanercept:  An overview.   Am Acad Dermatol 2003; 49 (2): S105-S111.

102.     Littenberg B, Partilo S, Licata A, Kattan M W.  Paper Standard Gamble:  the reliability of a paper questionnaire to assess utility.  Med Decis Making 2003; 23(6): 480-488.

103.     Mork C, Ozek M, Wahl A K.  Treatment or leisure?  Climate therapy of patients with psoriasis and psoriatic arthritis.  Tidsskr Nor Laegeforen 2004; 124(1): 60-62.

104.     Won C, Seo P, Park Y, Yang J, Lee K, Sung K, Park C, Kim D, Char Won Y, Kim K.  A Multicentre trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea.  J Dermatolog Treat 2004; 15(1): 30-34.

105.     Jenner N, Campbell J, Marks R.  Morbidity and cost of atopic eczema in Australia.  Australas J Dermatol 2004; 45(1): 16-22.

106.     Ganemo A, Sjoden P O, Johansson E, Vahlquist A, Lindbert M.  Health-related quality of life among patients with ichthyosis.  Eur J Dermatol  2004; 14(1): 61-66.

107.     Menter A, Kosinski M, Bresnahan B W, Papp K A, Ware J E Jr.  Impact of efalizumab on psoriasis-specific patient-reported outcomes.  Results from three randomized, placebo-controlled clinical trails of moderate to severe plaque psoriasis.  J Drugs Dermatol  2004; 3(1): 27-38.

108.     Whalley D, McKenna S P, Dewar A L. Erdman R A, Kohlmann T, Niero M, Cook S A, Crickx B, Herdman M J, Frech F, Assche D Van.  A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).  BJD 2004; 150: 274-283.

109.     Feldman S R, Menter A Koo JY.  Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.  BJD 2004; 150: 317-326.

110.     Lewis V L, Finlay A Y.  Ten years experience of the Dermatology Life Quality Index (DLQI)  J Investig Dermatol Symp Proc 2004; 9(2):169-180.

111.     Rhee J S, Matthews B A, Neuburg M, Smith T L, Burzynski M, Nattinger A B.  Skin cancer and quality of life:  assessment with the Dermatology Life Quality Index.  Dermatol Surg 2004; 30(4): 525-9.

112.     de Korte J, Sprangers M A G, Mombers F M C, Bos J D. Quality of life in patients with psoriasis: a systematic literature review.  J Investig Dermatol Symp Proc 2004; 9(2):140-147.

113.     Sampogna F, Sera F, Abeni D; IDI Multipurpose psoriasis research on vital experience (IMPROVE) investigators.  Measure of clinical severity, quality of life, and psychological distress in patients with psoriasis:  a cluster analysis.  J Invest Dermatol 2004; 122 (3): 602-607.

114.     Uttjek M, Dufaker M, Nygren L, Stenberg B.  Determinants of quality of life in a psoriasis population in northern Sweden.  Acta Derm Venereol 2004; 84(1):  37-43.

115.     Meding B, Wallenhammar L-M, Lindberg M, Nyfjall M.  Health-related quality of life and hand eczema.  Contact Dermatitis 2004; 50(3): 152-153.

116.     Zachariae R, Zachariae C, Ibsen H H, Mortensen J T, Wulf H C.  Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients.  Acta Derm Venereol 2004; 84: 205-212.

117.     Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri J M, Blanco J L, Jaen J, Navarro V, Massana G, Gatell J M.  Factors associated with severe impact of lipodystrophy on the quality of life of paints infected with HIV-1.  Clin Infect Dis 2004; 38(10): 1464-1470.

118.     Wallenhammar L M, Nyfjall M, Lindberg M, Meding B.  Health-related quality of life and hand eczema - a comparison of two instruments, including factor analysis.  J Invest Dermatol  2004; 122(6): 1381-1389.

119.     Yazici K, Baz K, Yazici A, Kokturk A, Tot S, Demirserent D, Butural   Disease-specific quality of life is associated with anxiety and depression in patients with acne.  J Eur Acad Dermatol Venereol 2004; 18(4): 435-439.

120.     Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer P J, Schneider D, Weidinger G, Braeutigam M.  Long-term efficacy and safety of pimcrolimus cream 1% in adults with moderate atopic dermatitis.  Dermatology 2004; 208: 365-372.

121.     Zaghloul S S, Goodfield M J D.  Objective assessment of compliance with psoriasis treatment.  Arch Dermatol 2004; 140: 408-414.

122.     Wallenhammar L-M, Nyfjall M, Lindberg M, Meding B.  Health-related quality of life and hand eczema - A comparison of two instruments, including factor analysis.  JID 2004; 122(6): 1381-1387.

123.     Szepietowski,J, Salomon J, Finlay A Y, Klepacki A, Chodynicka B, Marionneau N, Taieb C, Myon E.  DLQI:  Polish version.  Dermatlogia Kliniczna 2004; 6(2): 63-70.

124.     Augustin M, Wenninger K, Amon U, Schroth M J, Kuster W. Chren M, Kupfer J, Gieler U.  German adaptation of the Skindex-29 questionnaire on quality of life in dermatology:  Validation and clinical results.  Dermatology 2004; 209: 14-20.

125.     Lennox R D, Leahy M J.  Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.  Ann Allergy Asthma Immunol  2004; 93(2): 142-146.

126.     Holm E A, Esmann S, Jemec G B E.  Does visible atopic dermatitis affect quality of life more in women than in men?  Gender Medicine 2004; 1(2): 125-130.

127.     Finlay A Y Quality of Life Indices.  Indian J Dermatol Venereol Leprol 2004; 70: 144-149.

128.     Tan S R, Whitney D T.  Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life.  JAAD 2004; 51(4) 592-599.

129.     Gottlieb A B, Evans R, Li S, Dooley L T, Guzzo C A, Baker D, Bala M, Marano C W & Menter A.  Infliximab induction therapy for patients with severe plaque-type psoriasis:  A randomized, double-blind, placebo-controlled trialJAAD 2004; 51(4) 534-542.

130.     Wittkowski A, Richards H L, Griffiths C E, Main C J.  The impact of psychological and clinical factors on quality of individuals with atopic dermatitis.  J Psychosom Res 2004; 57(2):  195-200.

131.     Menter A, Gordon K, Carey W, Hamliton T, Glazer S, Caro I, Li N, Gulliver W.  Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.  Arch Dermatol 2005; 141(1) 31-38.

132.     Ruzicka T, Larsen F G, Galewicz D, Horvath A, Coenraads P J, Thestrup-Pedersen K, Ortonne J P, Zouboulis C C, Harsch M, Brown T C, Zultak M.  Oral Alitetinoin (9-cis-retinoic acid) Therapy for chronic hand dermatitis in patients refractory to standard therapy.  Arch Dermatol 2004; 140: 1453-1459.

133.     Charman C R, Venn A J, Williams H C.  The patient-oriented eczema measure.  Arch Dermatol 2004; 140: 1513-1519.

134.     Wells M, Macmillan M, Raab, G, Macbride S, Bell N, MacKinnon K, MacDougall H,
Samuel L, Munro A.  Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reaction?  A randomised controlled trial.  Radiother Oncol 2004; 73(2):  153-162.

135.     Wang X L, Zhao T E, Zhang X O.  Assessment on the reliability and validity of the Dermatology Life Quality Index in Chinese version.  Zhonghau Liu Xing Bing Xue Za Zhi 2004; 25(9): 791

136.     ztas P, Calikoglu E, Cetin I.  Psychiatric test in seborrhoeic dermatitis.  Acta Derm Venereol 2005; 85: 68-69.

137.     Tjioe M, Otero M E, van der Kerkhof P C M, Gerritsen M J P.  Quality of life in vitiligo patients after treatment with long-term narrowband ultraviolet B phototherapy.  JEADV 2005; 19: 56-60.

138.     Polderman M C, Wintzen M, Cessie S, Pavel S.  UVA-1 cold light therapy in the treatment of atopic dermatitis patients treated in the Leiden University Medical Center.  Photodermatol Photoimmunol Photomed 2005; 21(2):93-96.

139.     Schmitt J, Wozel G.  The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis.  Dermatology 2005; 210: 194-199.

140.     Jacobi A, Antoni C, Manger B, Schuler G, Hertl M.  Infliximab in the treatment of moderate to severe atopic dermatitis.  J Am Acad Dermatol 2005; 52(3): 522-526.

141.     Holm E A, Esmann S, Jemec.  Patient Education and morbidity in atopic eczemaDermatol Nursing 2005; 17(1): 35-45.

142.     Chuh A A, Chan H H.  Effect on quality of life in patients with pityriasis rosea:  Is it associated with rash severity?  Int J Dermatol 2005; 44(5): 372-377.

143.     Finlay A Y.  Current severe psoriasis and the Rule of Tens.  BJD 2005; 152: 861-867.

144.     Polderman M C, Wintzen M, Cessie S, Pavel S.  UVA-1 cold light therapy in the treatment of atopic dermatitis:  61 patients treated in the Leiden University Medical Center.  Photodermatol Photoimmunol Photomed 2005; 21(2):93-96.

145.     Weiss S C, Nguyen J, Chon S, Kimball A B.  A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-terms treatment of stasis dermatitis.  J Drugs Dermatol 2005; 4(3): 339-345.

146.     Zaghloul S S, Cunliffe W J, Goodfield M J D.  Objective assessment of compliance with treatments in acne.  BJD 2005; 152:  1015-1021.

147.     Feldman S R, Gordon K B, Bala M, Evans R, Dooley L T, Guuzzo C, Patel K, Menter A, Gottlieb A B.  Infliximab treatment results in significant improvement in the quality of life of patients with sever psoriasis:  a double-blind placebo-controlled trial.  BJD 2005; 152:  954-960.

148.     Ongenae K, Dierckxsen L, Brochez L, van Geel N, Naeyaert J M.  Quality of life and stigmatization profile in a cohort of vitiligo patients an effect of the use of camouflage.  Dermatology 2005; 210: 279-285. 

149.     McKenna S P, Lebwhol M, Kahler K N.  Development of the US PSORIQoL:  A psoriasis-specific measure of quality of life.  Intern J of Dermatol 2005; 44: 462-469.

150.     Ongenae K, Van Geel N, De Schepper S, Naeyaert J M.  Effect of vitiligo on self-reported health -related quality of life.  BJD 2005; 152: 1165-1172.

151.     Katugampola R P, Hongbo Y, Finlay A Y.  Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life.  BJD 2005; 152: 1256-1262.

152.     Yahathugoda T C, Wickramasinghe D, Weerasooriya M V, Samarawickrema W A.  Lymphoedema and its management in cases of lymphatic filariasis:  the current situation in three suburbs of Matara, Sri Lanka, before the introduction of a morbidity-control programme.  Ann Trop Med Parasitol 2005; 99: (5): 501-510.

153.     Mayrshofer F, Hertl M, Sinkgraven R, Sticherling M, Pfeiffer C, Zillikens D, Messer G, Rzany Fur Die Deutschebsd-Studiengrouppe B.  Significant decrease in quality of life in patients with pemphigus vulgaris.  Results from the German Bullous Skin Disease (BDS) Study Group.  J Dtsch Dermatol Ges. 2005; 3(6): 431-435.

154.     Shikiar R, Harding G, Leahy M, Lennox R D.  Minimal Important Difference (MID) of the Dermatology Life Quality Index  (DLQI):  Results from patients with chronic idiopathic urticaria.  Health Qual Life Outcomes 2005;3: 36.

155.     Moloney F J, Keane S, O’Kelly P, Conlon P J, Murphy G M.  The impact of skin disease following renal transplantation on quality of life.  Br J Dermatol 2005; 153 (3):  574-578.

156.     Hartmann A, Lurz C, Hamm H, Brocker E B, Hofmann U B.  Narrow-band UVB vs broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo.  Int J Dermatol 2005; 44(9): 736-742.

157.     Rottem M, Elbirt D, Sthoeger Z, Desloratadine Study Group.  Desloratadine for chronic idiopathic urticaria.  Harefuah 2005; 144(8): 547-553, 599, 598.

158.     Kondoh A, Ohta Y, Yamamoto K, Iwashita K, Umezawa Y, Matsuyama T, Ozawa A, Shinohara Y.  Feasibility of modified DLQI-based questionnaire for evaluation of clinical efficacy of herbal medicine in chronic skin diseases.  Tokai J Exp Clin Med 2005; 30(2):  97-102.

159.     Kulthanan K, Jiamton S, Wanitphakdeedecha R, Chantharujikaphong S.  The validity and reliability of the Dermatology Life Quality Index  (DLQI) in Thais.  Thai J Dermatol  2005; 20(3):  113-123.

160.     Smith C H, Anstey A V, Barker JNWN, Burden A D, Chalmers R J G, Chandle D, Finlay A Y, Griffiths C EM , Jackson S, McHugh N J, McKenna K E, Reynolds N J, Ormerod A D.  British Association of Dermatologist guidelines for use of biological interventions in psoriasis 2005. -  BJD 2005; 153: 486-497.

161.     Charman C R, Venn A J, Williams H, Bigby M.  Measuring atopic eczema severity visually.  Arch Dermatol:  2005; 141:  1146-1151.

162.     David S E, Ahmed Z, Salek M S, Finlay A Y.  Does enough quality of life-related discussion occur during dermatology outpatient consultations?  BJD 2005; 153: 997-1000.

163.     van de Kerkhof P, Griffiths C E M, Christophers E, Lebwohl M, Krueger G G.  Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.  Dermatology 2005; 211: 256-263.

164.     Hongbo Y, Thomas C L,. Harrison M A. Salek M S, Finlay A Y.  Translating the science of quality of life into practice:  what do Dermatology Life Quality Index scores mean?  JID 2005; 125 (4): 659-664.

165.     Babu B V, Nayak A N, Rth K, Kerketta A S.  Use of the Dermatology Life Quality Index  in filarial Lymphoedema patients.  Trans of the R Soc Trop Med & Hyg 2005; 11:

166.     Salisbury C, Nobel A, Horrocks S, Crosby Z, Harrison V, Coast J, de Berker D, Peters T.  Evaluation of a general practitioner with special interest service for dermatology randomised controlled trial.  BJM 2005 331: 1441-1443.

167.     Coast J, Noble S, Nobel A, Horrocks S, Asim O, Peters T J, Salisbury C.  Economic evaluation of a general practitioner with special interest led dermatology service in primary care.  BJM 2005 331: 1444-1448.

168.     Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P.  Psychometric properties of the Dermatology Life Quality Index  (DLQI) in 900 Italian patients with psoriasis.  Acta Derm Venereol 2005; 85: 409-413.

169.     Krueger G G, Langley R G, Finlay  A Y, Griffiths C E M, Woolley J M, Lalla D, Jahreis A.  Patient-reported outcomes of psoriasis improvement with etanercept therapy:  results of a randomized phase III trial.  BJD 2005; 153: 1192-1199.

170.     Picardi A, Mazzotti E, Gaetano P, Cattaruzza M S, Baliva G, Melchi DF, Biondi M,
Pasquini P.  Stress, social support, emotional regulation and exacerbation of diffuse plaque psoriasisPsychosomatics 2005; 46:  556-564.

171.     Feldman S R, Kimball A B, Krueger G G, Woolley J M, Llalla D, Jahreis A.  Etanercept improves the helath-related quality of life of patients with psoris:  Resutls of a phse III randomized clinical trial.  J Am Acad Dermatol 2005; 53:887-889.

172.     Ilgen E, Derya A.  There is no correlation between acne severity and AQOLS/DLQI scores.   Journal of Dermatology 2005; 32(9): 705-710.

173.     Innocenzi D, Lupi F, Bruni F, Frasca M, Panetta C, Milani M.  Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis:  a pilot exploratory trial.  Curr Med Res Opin 2005; 21(12): 1949-1953.

174.     Shah M, Coates M.  An assessment of the quality of life in odder patients with skin disease.  BJD 2005; 154: 150-153.

175.     Ortonne J P, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.  Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients:  results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial (NCT 00256139).  BMC Dermatol 2005; 5: 13.

176.     Sampogna F, Chren M M, Melchi E F, Pasquini P, Taboli S, Abeni D & The Italian Multipurpose Psoriasis research on Vital Experience (Improve)Study Group.  Age, gender, quality life and psychological distress in patients hospitalized with psoriasis.  BJD 2006; 154: 325-331

177.     Al-Buainian H, Gamal H, Cruz D, Alhayki N, Ongenae K, Naeyaert J N, allam M I.  The impact of vitiligo on quality of life in patients from Jeddah, Saudi Arabia. 

178.     Cvetkovski R S, Zachariae R, Jensen H, Olsen J, Johansen J D, Agne T.   Quality of life and depression in a population of occupational hand eczema patients.  Contact Dermatitis 2006; 54: 106-111.

179.     Cassano N, Loconsole F, Galluccio A, Icracapillo A, Pezza M, Vena G A.  Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis:  results of a pilot experience (power study).  Int J Immunopathol Pharmacol 2006; 19(1): 225-229

180.      Hundley J L, Carroll C L, Lang W, Snively B, Yosipovitch G, Feldman S R, Jorizzo J L.  Cutaneous symptoms of dermatomyositis significantly impact patients; quality of life. 
J Am Acad Dermatol 2006; 54 (2) 217.

181.      Ferraz L B, de Almeida F A, Vasconcellos M R, Faccina A S, Ciconelli R M, Ferraz M B.  the impact of lupus erythematosus cutaneous on the quality of life:  The Brazilian-Portuguese version of DLQI.  Qual Life Res 2006; 15(3) 565-570.

182.     Cusack C, Buckley C.  Etanercept:  effective in the management of hidradenitis suppurativa.  BJD 2006; 154: 726-729.

183.     Holm E A, Wulf H C, Stegmann H, Jemec G B E.  Life quality assessment among patients with atopic eczema.  BJD 2006; 154: 719-725.

184.     Holm E, Esmann S, Jemec G.  The handicap caused by atopic dermatitis - sick leave a job voidance.  JEADV  2006; 20(3): 255-259.

185.     Lachapelle J, Dexroix J, Henrijean A, Roquet-Gravy P, De Swerdt A, Boonen H, Lecuyer M, Suys E, Speelman G, Vastesaeger N.  Desloratadine 5mg once daily improves the quality of life of patients with chronic idiopathic urticaria.   JEADV 2006; 20(3): 288-292.

186.     Baron S E, Morris P K, Dye L, Fielding D, Goulden V.  The effect of dermatology consultations in secondary care on treatment outcome and quality of life in new adult patients with atopic dermatitis.  BJD 2006; 154: 942-949.

187.     Sampogna F, Tabolli S, Sderfeldt B, Axtelius B, Aparo U, Abeni D & IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators.  Measuring quality of life of patients with different clinical types of psoriasis using the SF-36.  BJD 2006; 154: 844-849.

188.     Meggitt S J, Gray J C, Reynolds N J.  Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema:  a double-blind, randomised controlled trial.  The Lancet 2006; 367: 839-846.

189.     Cvethkovski B S, Zachariae R, Jensen H, Olsen J, Johansen J D, Agner T.  Prognosis of occupational hand eczema.  Arch Dermatol 2006; 142: 305-311.

190.     Gordon K, Korman N, Frankel E, Want H, Jahreis, Zitnik R, Chang T.  Efficacy of etanercept in an integrated multi-study database of patients with psoriasis.  J Am Acad Dermatol2006; 54 (3): A101.

191.     Wahl A K, Mork C, Mork Lillehol B, Myrdal A M, Helland S, Hanestad B R, Moum T.  Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology.  Acta Derm Venereol 2006;  (86) 3: 198-201.

192.     Letter:  Nijsten T, Meades D M, McKenna S P.  Dimensionality of the Dermatology Life Quality Index  (DLQI): A Commentary. 
Reply:  Mazzoti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P.  Reply to letter by Nijsten T et al.  Acta Derm Venereol 2006;  (86) 3: 284-286.

193.     Smith C H, Jackson K, Bashir S J, Perex A chew A L, Powell A M, Wain M, Barker J N W N.  Infliximab for severe treatment-resistant psoiais:  a prospect, open-label studyBJD 2006 155: 160-169.

194.     Salim A, Tan E, Ilchyshyn A, Berth-Jones J.  Folic acid supplementation during treatment of psoriasis with methotrexate:  a randomized, double-blind, placebo-controlled trial.   BJD 2006; 154: 1169-1174.

195.     Reich K, Nestle F O, Papp K, Ortonne J-P, Wu Y, Bala M, Evans R, Guzzo C, Li S,
Dooley L T, Griffiths C E M.  Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis:  a randomized controlled trial.  BJD 2006; 154: 1161-1168.

196.     Wahl A K, Mork C, Hanestad B R, Helland S.  Coping with exacerbation in psoriasis and eczema prior to admission in a dermatological ward.  Eur J Dermatol 2006; 16(3): 271-275.

197.     Sunderkotter C, Weiss J M, Betermoller R, Loffler H, Schneider D.  Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus:  positive effects on major symptoms of atopic dermatitis and on quality of life.  J Dtsch Dermatol Ges 2006; 4(4): 301-306.

198.     Kapp A, Pichler W J.  Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria:  a randomized, double-blind, placebo-controlled, parallel, multicentre study.  Int J Dermatol 2006;45: 469-474.

199.     Nijsten T, Meads D M, McKenna S P.  Dimensionality of the Dermatology Life Quality Index (DLQI):  A Commentary.  Acta Derm Venereol 2006; 86(3): 284-285.

200.     van Geel N, Ongenae K, Vander Haeghen Y, Vervaet C, Naeyaert J M.  Subjective and objective evaluation of non-cultured epidermal cellular grafting for re-pigmenting vitiligo.  Dermatology 2006; 213(1): 23-29.

225.          Finlay A Y.  The DLQI:  A patient questionnaire can improve clinical decision-making in treating skin disease.  MIMS Dermatology 2006; 2(2): 12.

201.     Holme S A, Anstey A V, Finlay A Y, Elder G H, Badminton M N.  Erythropoietic protoporphyria in the UK:  clinical features and effect on qualify of life BJD 2006; 155: 574-581.

202.     Schmitt J M, Ford D E.  Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis.  Dermatology 2006; 213: 102-110.

203.     Letter:   Nijsten T, Meads D M, McKenna S P.  Dimensionality of the Dermatology Life      Quality Index  (DLQI):  A commentary.  Acta    Dermato-Venereol 2006; 86: 284-285.

204.     Gladman D D, Mease P J, Cifaldi M A, Perdok R J, Sasso E, Medich JAdalimumab improves joint - and skin-related functional impairment in patients with psoriatic arthritis:  Patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).  Ann Rhuem Dis 2006 Oct (E-Pub ahead of print).

205.     Conroy F J, Venus M, Monk B.  A qualitative study to assess the effectiveness of laser epilation using a quality-of-life scoring system.  Clin Exp Dermatol. 2006 31(6): 753-756.

206.     Shikiar R, Willian, M K, Okun M M, Thompson C S, Revicki D A.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients:  results of a phase II study.  Health Qual Life Outcomes 2006; 4: 71.

207.      Maroti M, Ulff E, Wijma B.  Quality of life before and 6 weeks after treatment in a dermatological outpatient treatment unit.  J Eur Acad Dermatol Venerol 2006; 9: 1081-1085.

208.     Takahashi N, Suzukamo Y, Nakamura M, Miyachi Y, Green J, Ohya Y, Finlay A Y,
Fukuhara S; Acne QoL Questionnaire Development Team.  Japanese version of the Dermatology Life Quality Index:  validity and reliability in patients with acne.  Health Qual Life Outcomes 2006; 4: 46.

209.     Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A.  Quality of life with vitiligo:  comparison of male and female Muslim patients in Iran.  Gend Med 2006; 2: 124-130.

210.     van Geel N, Ongenae K, Vander Haeghen Y, Vervaet C, Naeyaert J M.  Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo.  Dermatology 2006; 213(1): 23-29. 

211.     Gottlieb A B, Mease P J, Jackson M, Eisen D, Xia H A, Asare C, Stevens S R.  Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices.  J Derm Treat 2006;17:279-287.

212.     Vena G A, Cassano N, Colombo D, Peruzzi E, Pigatto P and the NEO-1-30 Study Group, Bari, Origio & Milan, Italy.  Cyclosporine in chronic idiopathic urticaria:  a double-blind, randomized, placebo-controlled trial.  J Am Acad Dermatol 2006; 55(4): 705-709.

213.     ztrkcan S, Ermertcan A.T, Eser E and Şahin M.T. Cross validation of the Turkish version of dermatology life quality index. International Journal of Dermatology 2006, 45, 1300-1307.

214.     van Coevorden A M, van Sonderen E, Bouma J, Coenraads P JJ.  Assessment of severity of hand eczema:  discrepancies between patient- and physician-rated scores.  BJD 2006; 155: 1217-1222.

215.     de Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S.  High-dose initiation of etanercept in psoriatic arthritis and plque psoriasis:  Efficacy, safety and impact on patient’s quality of life.  J Dermatol Treat 2006; 17: 355-358.

216.     Elewski B, Leonardi C, Gottlieb A B, Strober B E, Simiens M A, Dunns M, Jahareis A.  Comparison of clinical and pharmacokinetic profiles of etanercept 25mg twice weekly and 50mg one weekly in patient with psoriasis.  BJD 2007; 156: 138-142.

217.     Basra M K A, Sue-Ho R, Finlay AY.  The Family Dermatology Life Quality Index :  measuring the secondary impact of skin disease.  Br J Dermatol 2007; 156: 528-538.

218.     Weatherhead S C, Wahie S, Reynolds N J, Meggitt S J.  An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.  Br J Dermatol 2007; 156: 346-351.

219.     Schmitt J, Heese E, Wozel G, Meurer M.  Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a prospective study.  Dermatology 2007; 214: 68-76.

220.     Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Breautigam M, Ring J & Hofmann H.  Pimecrolimus cream 1% for papulopustular rosacea:  a randomized vehicle-controlled double-blind trial.  BJD 2006; 156: 728-732.

221.     Dalgard F, Finlay A Y.  Need and Greed in Dermatology:  Disease and outcome measures in dermatological healthcare planning.  Dermatology 2006; 213: 279-283.

222.     Takahashi N, Suzukamo Y, Kakamura M, Miyachi Y, Green J, Ohya Y, Finlay A Y.  Japanese version of the Dermatology Life Quality Index:  validity and reliability in patients with acne.  Health & Quality of Life Outcomes 2006; 4:46.

223.     Boehncke W-H, Brasie R A, Barker J, Chinenti S, Dauden E, de Rie M, Dubertret L, Giannetti A, Katsambas A, Kragballe K, Naeyaert J M, Ortonne J-P, Peyri J, Prinz J C,
Saurat J-H, Strohal R, van de Kerkhof  P.  Recommendations for the use of etanercept in psoriasis:  a European dermatology expert group consensus.  JEADV 2006; 20: 988-998.

224.     Bickers D R, Lim H W, Margolis D, Weinstock M A, Goodman C, Faulkner E, Gould C, Gemmen E, Dall T.  The burden of skin diseases:  2004.  A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. 
J Am Acad Dermatol 2006; 3: 490-500.

225.     Krueger G G, Langley R G, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L T, Lebwhohl M.  A human interleukin-12/23 Monoclonal antibody for the treatment of psoriasis.  N Engl J Med 2007; 356(6): 580-592.

226.     Schmitt J, Heese E, Wozel G, Meurer M.  Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a prospective study.  Dermatology 2007; 214: 68-76.

227.     Antoniou C, Stefanaki I, Stratigos A, Avgerinou G, Stavropoulos P, Potouridou I, Polidorou D, Moustou A E, Kosmadaki M & Katsambas A D.  The Greek experience with efalizumab in psoriasis from a university dermatologic hospital.  BJD 2007; 156 (Suppl 2): 12-16.

228.     Moore A, Gordon K B, Kang S, Gottlieb A, Freundlich B, Xia H A, Stevens S R.  A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.  J am Acad Dermatol 2007; 56(4): 598-603.

229.     Basra M K A, Sue-Ho R, Finlay A Y.  The Family Dermatology life Quality Index:  measuring the secondary impact of skin disease.  BJD 2007; 156: 528-538.

230.     Shikiar R, Heffernan M, Langley R G, Willian M K, Okun M M, Revicki D A.  Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis:  Patient-reported outcomes from a Phase II randomized controlled trial.  J Dermatol Treat 2007; 18: 25-31.

231.     Sampogna F, Gisondi P, Tabolli S, Abeni D & the IDI Multipurpose Psoriasis Research on Vital Experiences investigations.  Impairment of sexual life in patients with psoriasis.  Dermatology 2007; 214: 144-150.

232.     Schmitt-Egenolf M.  PsoReg - The Swedish registry for systemic psoriasis treatment. Dermatology  2007; 214: 112-117.

233.     Katugampola R P, Lewis VJ, Finlay A Y.  The Dermatology Life Quality Index:  assessing the efficacy of biological therapies for psoriasis.   Br J Dermatol 2007; 156: 945-950.

234.     Eghlileb A M, Davies E E G, Finlay A Y.  Psoriasis has a major secondary impact on the lives of family members and partners.  Br J Dermatol 2007; 156: 1245-1250.

235.     Schmitt J M, Ford D E.  Role of depression in quality of life for patients with psoriasis.  Dermatology 2007; 215: 17-27.

236.     Yones S S, Palmer R A, Garibaldinos T M, John R N, Hawk L M.  Randomized double-blind trial of treatment of vitiligo.  Arch Dermatol 2007; 143: 578-584.

237.     Tyring S, Kenneth B, Gordon M D, Poulin Y, Langley R, Gordon K, Gottlieb A, Dunn M, Jahreis A.  Long-term safety and efficacy of 50 mg etanercept twice weekly in patients with psoriasis.  Arch Dermatol 2007; 143: 719-723.

238.     Eghlileb A M, Finlay A Y.  Psoriasis has a major secondary impact on the lives of family members and partners.  Br J Dermatol 2007; 156: 1245-1249.

239.     Bechara F G, Gambichler T, Bader A, Sand M, Altmeyer P, Hoffmann K.  Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage.  J Am Acad Dermatol 2007; 56(2):207-212.

240.     Papoutsaki M, Chimenti M S, Costanzo A, Talamonti M, Zangrilli A, Giuta A, Bianchi L, Chimenti S.  Adalimumab for severe psoriasis and psoriatic arthritis:  an open label study in 30 patients previously treated with other biologics.  J Am Acad Dermatol 2007; 56(2):269-275.

241.     Garduno J, Bhosle M J, Balkrishnan R, Feldman S R.  Measures used in specifying psoriasis lesions(s), global disease and quality of life:  A systematic review.  J Dermatolog Treat 2007; 18(4): 223-242.

242.     Reich K, Nestle F O, Wu Y, Bala M, Eiseberg D, Guzzo C, Li S, Dooley L T, Griffiths C E.  Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.  Eur J Dermatol 2007; 17(5):  381-386.

243.     Mozaffari H, Pourpack Z, Pourseyed S, Farhoodi A, Aghamohammadi A, Movahadi M, Gharaghozloom, Moin M.  Quality of life in atopic dermatitis patients.  J Microbiol Immunol Infect 2007; 40(3): 260-264.

244.     Coghi S, Bortoletto M C, Sampaio S A, Andrade Jr HF, Aoki V.  Quality of life is severely compromised in adult patients with atopic dermatitis in Brazil, especially due to mental components.  Clinics 2007; 63(3):  235-242.

245.     Al-Ghnaniem R, Short K, Pullen L C, Rennie J A, Leather A J.  1% hydrocortisone ointment is an effective treatment of pruritus ani:  a pilot randomized controlled crossover trialInt J Colorectal Dis 2007; May (E-pub).

246.     Nijsten T, Mweads D M, dr Korte J, Samponga F, FGelfand J M, Ongenae k, Evers A W, Augustin M.  Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients.  J Invest Dermatol 2007; May (E-pub).

247.     Belhadjali H, Amri M, Meecheri A, Doarika A, Khorchani H, Youssef M, Gaha , Zili J.  Vitiligo and quality of life: a case-control study (Article in French).  Ann Dermatol Venereol 2007; 134 (3 Pt 1) 233-236.

248.     Spector S L, Shikiar R, Harding G, Meeves S, Leahy M J.  The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria.  Cutis 2007; 79(2): 157-162.

249.     Mazharinia N, Aghaei S, Shayan Z.  Dermatology Life Quality Index (DLQI) scores in burn victims after revival.  J Burn Care Res 2007; 28(2):  312-317.

250.     Schffski O, Augustin M, Prinz J, Runder K Schubert E, Sohn S, Reich K.  Cost and quality of life in patients with moderate to severe plaque-type psoriasis in Germany:  a multi-centre study (article in German).  J Dtsch Dermatol Ges 2007; 5(3): 209-218.

251.     Rhee J S, Matthews B A, Neuburg M, Logan B R, Burzynski M, Nattinger A B.  The skin cancer index:  clinical responsiveness and predictors of quality of life.  Laryngoscope 2007; 117(3): 399-405.

252.     Campanati A, Bernardini M L, Gesuita R, Offidani A.  Plantar focal idiopathic hyperhidrosis and botulinum toxin:  a pilot study.  Eur J Dermatol  2007; 17(1): 52-54 (E-Pub).

253.     Misery L, Finlay A Y, Martin N, Boussetta S, Nguyen C, Myon E, Taieb C.  Atopic dermatitis:  impact on the quality of life of patients and their partners.  Dermatology 2007; 215(2): 123-129.

254.     Both H, Essink-Bot M-L, Busschback J, Nijsten T.  Critical review of generic and dermatology-specific health-related quality of life instruments.  JID 2007; 127: 2726-2739.

255.     Salek S, Roberts A, Finlay A Y.  The practical reality of using patient-reported outcome measures in a routine dermatology clinic.  Dermatology 2007 215: 315-319.

256.     Evers A W M, Duller P, van de Kerkhof P C M, van der Valk P G M, de Jong E M G J, Gerritsen M J P, Otero E, Verhoeven E W M, Verhaak C M, Kraaimaat F W.  The impact of chronic skin disease on daily life (ISDL): a generic and dermatology-specific health instrument.  Br J Dermatol 2007; 158: 101-108.

257.     Revicki D, Willian M K, Saurat J-H, Papp K A, Ortonne J-P, Sexton C, Camez A.  Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes:  results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.  Br J Dermatol 2008; 158: 549-557.

258.     Quandt S A, Schulz M R, Vallejos Q M, Feldman S R, Verma A, Fleischer A B, Rapp S R, Arcury T A..  The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farm workers.   ID 2008; 47: 236-241.

259.     Flystrm I, Stenberg B, Svensson , Bergbrant I-M.  Methotrexate vs ciclosporin in psoriasis:  effectiveness, quality of life and safety.  A randomized controlled trial.  Br J Dermatol 2008; 158: 116-121.

260.     Revicki D A, Willian M K, Menter A, Gordon K B, Kimball A B, Leonardi C L, Langley R G, Kimel M, Okun M.  Impact of adalimumab treatment on patient-reported outcomes:  Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.   JID 2007; 18: 341-350

261.     Grob J J, Auquier P, Dreyfus I, Ortonne J P.  Quality of life in adults with chronic idiopathic urticaria receiving Desloratadine:  a randomized, double-blind, multicentre, placebo-controlled study.  JEADV 2008 22: 87-93.

262.     Schmitt J, Meurer M, Klon M Frick K D.  Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema:  a population-based study.   Br J Dermatol 2008; 158: 351-359.

263.     Carroll C L, Lang W, Snively B, Feldman S R, Callen J, Jorizzo  J L.  Development and validation of the Dermatomyositis Skin Severity Index.  Br J Dermatol 2008; 158:
345-350.

264.     Woods A L, Rutter K J, Gardner L S, Lewis V J, Saxena S, George S A, Chalmers R J G, Griffiths C E M, Speight E L, Anstey A V, Ronda L, McGibbon D, Barker J W N, Smith C H.  Inpatient management of psoriasis:  a multicentre service review to establish national admission standards.  Br J Dermatol 2008; 158: 266-272.

265.     Gokdemir G, Ari S, Kşl A.  Adherence to treatment in patients with psoriasis vulgaris:  Turkish experience.  JEADV 2008; 22: 330-335.

266.     Davies E, Patel C, Salek M S, Finlay A Y.  Does ad hoc quality of life discussion in inflammatory skin disease consultations reflect standardized patient-reported outcomes?    Clinical & Experimental Dermatology 2008; 33: 16-21.

267.     Mekkes J R, Bos J D.  Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.  BJD 2008; 158: 370-374.

268.     Nelson A A, Pearce D J, Fleischer A B, Balkrishnan R, Feldman S R.  Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.  J Am Acad Dermatol 2008; 58: 125-135.

269.     Zachariae R, Zachariae C O C, Lei U, Pedersen A F.  Affective and sensory dimensions of pruritus severity:  associations with psychological symptoms and quality of life in psoriasis patients.  Acta Derm Venereol 2008; 88: 121-127.

270.     Bender B G, Ballard R, Canono B, Murphy RJ R, Leung D Y M.  Disease severity, scratching and sleep quality of patients with atopic dermatitis.  J Am Acad Dermatol 2008; 58: 415-420.

271.     Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M.  Pimecrolimus 1% cream in the treatment of facial psoriasis:   A 16 week open-label study.  Dermatology 2008; 216: 133-136.